Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.44% | 41.60% | 48.71% | 49.99% | 63.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.09% | 54.53% | 62.12% | 60.02% | 73.08% |
| Operating Income | -47.09% | -54.53% | -62.12% | -60.02% | -73.08% |
| Income Before Tax | 65.97% | 32.30% | -114.41% | -154.17% | -245.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.97% | 32.30% | -114.41% | -154.17% | -245.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.97% | 32.30% | -114.41% | -154.17% | -245.63% |
| EBIT | -47.09% | -54.53% | -62.12% | -60.02% | -73.08% |
| EBITDA | -46.53% | -53.58% | -93.38% | -154.65% | -341.43% |
| EPS Basic | 72.25% | 48.16% | -56.77% | -83.78% | -139.16% |
| Normalized Basic EPS | 72.26% | 40.08% | -105.34% | -145.46% | -233.54% |
| EPS Diluted | 72.25% | 48.16% | -56.77% | -83.78% | -139.16% |
| Normalized Diluted EPS | 72.26% | 40.08% | -105.34% | -145.46% | -233.54% |
| Average Basic Shares Outstanding | 18.31% | 16.45% | 11.23% | 6.55% | 2.57% |
| Average Diluted Shares Outstanding | 18.31% | 16.45% | 11.23% | 6.55% | 2.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |